USPTO serial 97524671
ZEPHYR AI
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- RINKER, ANTHONY MICHAEL
- Law office
- TMO LAW OFFICE 119
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with ZEPHYR AI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $772*
Plus Government fees of $375
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Dallas, TX, US
Dallas, TX, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Won
Karen Won Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo P.C.One Financial CenterBoston, MA 02111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer programs using artificial intelligence for machine learning; downloadable software using artificial intelligence for machine learning for scientific and medical research and development; downloadable computer software, software platforms, downloadable mobile applications, and downloadable software programs using artificial intelligence and machine learning technologies for scientific and medical research and development; downloadable computer programs using artificial intelligence for machine learning in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals | ACTIVE | — |
| 042 | Scientific research consulting services in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; scientific and medical research analysis of healthcare, medical, genetic, scientific, biologic, clinical and oncologic data; scientific research consulting in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; genetic and tumor mapping for scientific and medical research purposes; providing medical and scientific research information in the fields of genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; drug discovery services; scientific services, namely, analyzing medical, genetic, oncological, biological and diabetes-related data for treatment and diagnostic purposes by using machine learning and artificial intelligence technologies; providing scientific, medical and clinical research and scientific, medical and clinical research consulting services in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals by using machine learning, artificial intelligence technology, and biotechnology; medical and scientific research and consulting, namely, designing and organizing clinical trials for others; research and development services in the creation of databases and collections of information and data on biologicals for research purposes; providing genetic reference databases being collections of gene sequences for research purposes; disease modeling for research purposes; scientific analysis services, namely, services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, diabetes, and other diseases; pharmaceutical drug development services; genetic research for identifying biomarker rankings for medical purposes; research and development of pharmaceutical preparations and medicines; consulting services in the field of pharmaceutical research and development; medical and scientific research in the field of medical treatment and diagnosis, including for cancer and diabetes; providing temporary use of online non-downloadable software, cloud-based software, platform as a service (PAAS) featuring computer software platforms, and a website featuring technology, all for enabling users to use artificial intelligence for machine learning in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; software design and development; software installation and maintenance; DNA analysis services for scientific and medical research purposes; application service provider (ASP) featuring software using artificial intelligence for machine learning | ACTIVE | — |
| 044 | Healthcare;medical services;consulting services in the field of healthcare, medicine, and medical use of pharmaceuticals; healthcare, medical, and pharmaceutical medical use information services; DNA screening for medical purposes; clinical medical consultation services; healthcare, medical, and pharmaceutical services, namely, providing databases in the fields of medical, scientific, genetic, oncological, and biological information for inputting, collecting, analyzing, and managing data for treatment and diagnostic purposes; healthcare and medical services, namely, analyzing medical, genetic, oncological, biological and diabetes-related data for treatment and diagnostic purposes by using machine learning and artificial intelligence technologies; providing medical consulting services in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals by using machine learning, artificial intelligence technology, and biotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 22, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 21, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 20, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 19, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 19, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 18, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 18, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 18, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 8, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 8, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 8, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 8, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 8, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 22, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 21, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 21, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 21, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 14, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 13, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 13, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 19, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 4, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 3, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 3, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 3, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 22, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 22, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 22, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 22, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 21, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 26, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 26, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 6, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 22, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 22, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 22, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 22, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 22, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 14, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Aug 14, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 14, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 14, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 13, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 13, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 17, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 17, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 17, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 15, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 1, 2022 | NWAP | NEW APPLICATION ENTERED | — |